Health product recall

PMS-Pazopanib 200 mg tablet; Presence of Sorafenib

Last updated

Summary

Product
PMS-Pazopanib 200 mg tablet
Issue
Health products - Product quality
What to do

Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.

Affected products

Brand

Product Name

Market Authorization

Dosage Form

Strength

Lot number

Pharmascience

PMS-Pazopanib 200 mg tablet

DIN 02525666

Tablet

Pazopanib hydrochloride 200 mg

E0201K, E0201J

Issue

Presence of Sorafenib in affected lots.

What you should do

  1. Verify if your product is affected.
  2. Contact the recalling firm if you have any questions about the recall.
  3. Report any health product related side effects to Health Canada.
  4. Report any other health product safety complaints to Health Canada.

Additional information

Background

Depth of recall: Retailers

Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies

Pharmascience Inc.

6111 Avenue Royalmount, 

Montréal, Québec, H4P 2T4, Canada

Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-73740

Get notified

Receive notifications for new and updated recalls and alerts by category.

Subscribe